Predictive Oncology Inc. announced the appointment of Christoph Reinhard, Ph.D., MBA, to its Scientific Advisory Board. In this role, Dr. Reinhard will serve alongside other key thought leaders in their respective fields to guide the Company's scientific initiatives and growth strategy. Dr. Reinhard is a leader in oncology translational research, new technologies in drug development, and external innovation.

As acting Chief Scientific Officer for CELLphenomics GmbH, he plays an instrumental role in determining what types of novel drugs and drug combinations might be beneficial to future cancer patients with solid tumors. For more than a decade, Dr. Reinhard worked at Eli Lilly where he was responsible for strategy development and implementation of translational research support for its oncology portfolio assets, as well as the cross-functional alignment and resourcing of oncology biomarker efforts. He spearheaded the company's Innovative Medicine Initiative in Oncology and was directly involved in the development and implementation of the Partners and Outsourcing Strategy for Lilly Singapore's drug development and biomarker efforts.

He is also the co-founder and Director of the Board of Asian Cancer Research Group (ACRG). Dr. Reinhard holds a Ph.D. from the Biocenter University, Basel, Switzerland; an MBA in Technology Management from Phoenix University and a Bachelor of Science in Molecular Biology, Biochemistry and Microbiology from the University of Freiburg in Germany.